免疫检查点抑制剂相关糖尿病的NCI临床试验大型分析
IMPORTANCE: Immune-related adverse events (IRAEs) limit the use of cancer immunotherapy. Understanding the risk of severe IRAEs may help improve the use of cancer immunotherapy.…
要点
- ICI-D总体累积发生率为0.52/100例,属罕见但高致残性不良事件。
- 联合免疫治疗较单药增加ICI-D风险(OR 2.68),同步化疗降低风险(OR 0.38)。
- 确诊时90%需住院、43%需重症监护,医疗负担高。
核心结论
- ICI-D为罕见但高致病性的免疫相关不良事件,其风险随ICI联合方案不同而变化。
主要发现
- ICI-D总体累积发生率为0.52/100例治疗患者。
- 联合免疫治疗者ICI-D发生率为0.94%,PD-1/PD-L1单药治疗者为0.37%(OR 2.68,95%CI 1.69-4.24)。
- 确诊ICI-D时90%需住院,43%需重症监护。
- 较高血糖水平更可能提示ICI-D而非其他高血糖病因。
临床怎么用
- 接受含PD-1/PD-L1抑制剂方案的患者应监测高血糖,尤其联合免疫治疗者。
- 出现高血糖时需鉴别ICI-D与其他病因,较高血糖水平更支持ICI-D。
- 确诊ICI-D后需警惕高住院率和重症监护需求,及时评估病情严重度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Immune-related adverse events (IRAEs) limit the use of cancer immunotherapy. Understanding the risk of severe IRAEs may help improve the use of cancer immunotherapy. OBJECTIVE: To review and assess hyperglycemic events across thousands of patients to characterize immune checkpoint inhibitor (ICI)-induced diabetes (ICI-D) using a large-scale trial conglomerate. DESIGN, SETTING, AND PARTICIPANTS: Adverse event (AE) reports related to diabetes, hyperglycemia, and acidosis were retrieved from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) database. Trial data from June 2015 to December 2022 were analyzed. Clinical information was manually retrieved. Overall counts of patients on each trial were retrieved from central NCI data. NCI CTEP trials are hosted in both academic and community medical centers. This analysis includes patients across 158 trials who were treated with varying regimens that included programmed cell death 1 protein (PD-1) or programmed cell death 1 ligand 1 (PD-L1) inhibitors through an NCI CTEP trial for their cancer from June 2015 to December 2022. Data clarifications were requested and then data were analyzed from January 2023 to June 1, 2025. MAIN OUTCOMES AND MEASURES: Clinical characteristics differentiating ICI-D from other causes of hyperglycemia were enumerated. Cumulative incidence rates of ICI-D were calculated using trial-level data. Logistic regression was used to calculate the odds of developing ICI-D. RESULTS: In 13 966 patients across 158 trials, the overall cumulative incidence of ICI-D was low (0.52 per 100 treated patients), but incidence varied by treatment type and was lower if patients were exposed to concurrent chemotherapy (0.65% without chemotherapy vs 0.26% with chemotherapy; odds ratio [OR], 0.38; 95% CI, 0.21-0.71; P = .002) and higher if patients were exposed to combined immunotherapy (0.94% with combination immunotherapy vs 0.37% with PD-1/PD-L1 inhibitor monotherapy; OR, 2.68; 95% CI, 1.69-4.24). Despite these low rates, the health care burden of ICI-D was high, with 90% requiring hospitalization at diagnosis and 43% requiring intensive care. The degree of hyperglycemia can be used to differentiate different etiologies of hyperglycemia, with higher glucose levels being more likely to be due to ICI-D. CONCLUSIONS AND RELEVANCE: Results of this study suggest that ICI-D is a rare but morbid condition that varies based on the combination of ICIs with other agents.
引用
- Quandt ZE, Finnigan S, Hill V, et al. Immune Checkpoint Inhibitor-Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 Agents. JAMA Oncol. 2026. PMID: 41452607. doi:10.1001/jamaoncol.2025.5594
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。